Business Daily Media

Business Marketing

.

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia

  • Written by ACN Newswire - Press Releases

Eisai Launches New Insomnia Drug Dayvigo (Lemborexant) CIV in the United States as a Treatment Option for Adults With Insomnia

TOKYO, Jun 2, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has launched its in-house discovered orexin receptor antagonist DAYVIGO (lemborexant) CIV for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance in the U.S. on June 1, 2020.Discovered

Read more //?#

Popular

Rackspace Technology launches new category in Cloud Services

Designed with cloud native thinking, this ‘do with’ approach gives customers on-demand access to a dedicated pod of cloud engineers working alongside their team to deliver cloud outcomes while empowering ongoing innovation R...

The ultimate checklist for choosing a Forex broker in Singapore

Choosing a reliable broker to invest with isn’t always easy. Singapore financial experts have outlined eight tips on how to find a trustworthy broker to start trading Forex. Forex trading is getting bigger every day. With so ...

How to create a BFSI app experience that is both seamless, and secure

During a time of rapid change for the local banking and finance sector, legacy banks and financial services institutions (FSIs) face unique operational challenges. Many of them have to rapidly expand their digital service of...

Virtual Office
Tomorrow Business Growth